PILA Pharma Begins Dosing Participants in 12-Week Obesity Trial
PILA Pharma dosed the first two participants in PP-CT04, a randomized, double-blind, placebo-controlled study of oral TRPV1 antagonist XEN-D0501, titrated up to 16 mg twice daily.
PILA Pharma dosed the first two participants in PP-CT04, a randomized, double-blind, placebo-controlled study of oral TRPV1 antagonist XEN-D0501, titrated up to 16 mg twice daily.